Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy — Grace H. Attrill (2022) | RDL Network
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
Article 2022 en
Authors
GA
Grace H. Attrill
CO
C. Owen
TA
Tasnia Ahmed
Abstract
1 min read
Adjuvant immunotherapy-treated patients with a high proportion of CD39+ Trms in their baseline melanoma resection have a significantly reduced risk of melanoma recurrence. This population of T cells may not only represent a biomarker of RFS following anti-PD-1 therapy, but may also be an avenue for therapeutic manipulation and enhancing outcomes for immunotherapy-treated patients with cancer.
Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison M. Weppler, Geoffrey Peters, Afaf Abed, Megan Lyle, Muhammad Adnan Khattak, Andrew Haydon, Matteo S. Carlino, Shahneen Sandhu, Georgina V. Long, Alexander M. Menzies
Wei Yen Chan, Jenny Lee, Ashleigh Stewart, Russell J. Diefenbach, Maria Gonzalez, Alexander M. Menzies, Christian U. Blank, Richard A Scolyer, Georgina V. Long, Helen Rizos
Tuba N. Gide, Nurudeen A. Adegoke, Michael Xie, Yizhe Mao, Grace H. Attrill, Nigel Maher, Robyn P.M. Saw, Ismael A. Vergara, Matteo S. Carlino, Serigne Lo, Inês Pires da Silva, Jorja Braden, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long, James S. Wilmott
Jarem Edwards, James S. Wilmott, Jason Madore, Tuba N. Gide, Camelia Quek, Annie Tasker, Angela L. Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, Richard A Scolyer, Umaimainthan Palendira
Discussion(0)
No comments yet. Be the first to comment.